MENU
ADMA
AS OF
Feb 4, 03:47 PM (EDT)
Price
$16.60
Change
-$0.92 (-5.25%)
Capitalization
4.17B
43 days until earnings call
Intraday BUY SELL Signals
+Compare
ADMA
Stock ticker: NASDAQ
AS OF
Feb 4, 03:47 PM (EDT)
Price
$16.60
Change
-$0.92 (-5.25%)
Capitalization
4.17B

ADMA ADMA Biologics Forecast, Technical & Fundamental Analysis

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more

Industry: #Biotechnology
ADMA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ADMA with price predictions
Feb 03, 2026

ADMA sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ADMA moved above the 200-day moving average on January 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ADMA's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where ADMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on February 03, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADMA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ADMA moved below its 50-day moving average on January 15, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ADMA crossed bearishly below the 50-day moving average on January 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ADMA entered a downward trend on February 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.671) is normal, around the industry mean (27.519). P/E Ratio (20.372) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (8.826) is also within normal values, averaging (331.843).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ADMA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ADMA is expected to report earnings to rise 24.47% to 18 cents per share on March 19

ADMA Biologics ADMA Stock Earnings Reports
Q4'25
Est.
$0.19
Q3'25
Est.
$0.15
Q2'25
Missed
by $0.01
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.31
The last earnings report on November 05 showed earnings per share of 15 cents, meeting the estimate of 15 cents. With 126.80K shares outstanding, the current market capitalization sits at 4.17B.
A.I. Advisor
published General Information

General Information

an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
465 State Route 17
Phone
+1 201 478-5552
Employees
624
Web
https://www.admabiologics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPCLX15.860.04
+0.25%
Calamos Phineus Long/Short C
VWINX25.850.03
+0.12%
Vanguard Wellesley® Income Inv
FSCHX13.24N/A
N/A
Fidelity Select Chemicals
GVEQX151.19-0.64
-0.42%
Government Street Equity
FRSIX14.70-0.27
-1.80%
Franklin Small-Mid Cap Growth C

ADMA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VIR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+0.11%
VIR - ADMA
46%
Loosely correlated
-0.39%
IMTX - ADMA
40%
Loosely correlated
-0.40%
CPRX - ADMA
40%
Loosely correlated
+0.88%
RGNX - ADMA
40%
Loosely correlated
+0.74%
XENE - ADMA
39%
Loosely correlated
+1.62%
More